Janssen to Use Adaptive's NGS Immune Profiling Assay to Study Drug Response | GenomeWeb

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies said today that it has inked a biomarker discovery agreement with Janssen Research & Development.

Under the terms of the agreement, which was facilitated by the Johnson & Johnson Innovation Center, Adaptive will use its targeted next-gen sequencing-based ImmunoSeq assay to study immune response to diseases in order to identify patients more likely to respond to immunology and oncology drugs being developed by Janssen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.